Choi et al [36] monitored ctDNA in serial blood samples from CRC patients on anti-EGFR therapy using Guardant360 NGS panel, and observed multiple emerging genetic alterations associated with treatment resistance. Here, EGFR is linked to colorectal carcinoma.